The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

BACKGROUND: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled tri...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Palandri, Francesca, Castagnetti, Fausto, Alimena, Giuliana, Testoni, Nicoletta, Breccia, Massimo, Luatti, Simona, Rege-Cambrin, Giovanna, Stagno, Fabio, Specchia, Giorgina, Martino, Bruno, Levato, Luciano, Merante, Serena, Liberati, Anna Maria, Pane, Fabrizio, Saglio, Giuseppe, Alberti, Daniele, Martinelli, Giovanni, Baccarani, Michele, Rosti, Gianantonio
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2009
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2635408/
https://ncbi.nlm.nih.gov/pubmed/19144656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.13529
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы